|
Proportion of study population, %
|
100
|
69.6
|
17.8
|
12.6
|
|
Median follow-up (range), months
|
9.2 (0.0–42.7)
|
7.9 (0.0–42.7)
|
12.7 (0.1–37.3)
|
16.3 (0.1–37.1)
|
|
Median age at diagnosis (range), years
|
68 (28–93)
|
68 (28–88)
|
67 (48–90)
|
70 (32–93)
|
|
Sex, n (%)
|
|
Male
|
541 (53.9)
|
395 (56.6)
|
94 (52.5)
|
52 (41.3)
|
|
Female
|
462 (46.1)
|
303 (43.4)
|
85 (47.5)
|
74 (58.7)
|
|
Tumor histology, n (%)
|
|
Adenocarcinoma
|
635 (63.3)
|
387 (55.4)
|
131 (73.2)
|
117 (92.9)
|
|
Squamous cell carcinoma
|
243 (24.2)
|
202 (28.9)
|
38 (21.2)
|
3 (2.4)
|
|
Large cell carcinoma
|
6 (0.6)
|
4 (0.6)
|
2 (1.1)
|
0
|
|
Not specified
|
119 (11.9)
|
105 (15.0)
|
8 (4.5)
|
6 (4.8)
|
|
TNM stage at diagnosis, n (%)
|
|
T
|
|
T X-4
|
938 (93.5)
|
647 (92.7)
|
170 (95.0)
|
121 (96.0)
|
|
N/A
|
65 (6.5)
|
51 (7.3)
|
9 (5.0)
|
5 (4.0)
|
|
N
|
|
N X-3
|
939 (93.6)
|
648 (92.8)
|
170 (95.0)
|
121 (96.0)
|
|
N/A
|
64 (6.4)
|
50 (7.2)
|
9 (5.0)
|
5 (4.0)
|
|
M
|
|
M1a
|
524 (52.2)
|
351 (50.3)
|
114 (63.7)
|
59 (46.8)
|
|
M1a
|
166 (16.6)
|
120 (17.2)
|
22 (12.3)
|
24 (19.0)
|
|
M1b
|
310 (30.9)
|
224 (32.1)
|
43 (24.0)
|
43 (34.1)
|
|
M1c
|
3 (0.3)
|
3 (0.4)
|
0
|
0
|
|
ECOG PS score at diagnosis, n (%)
|
|
0–1
|
759 (75.7)
|
513 (73.5)
|
157 (87.7)
|
89 (70.6)
|
|
2+
|
244 (24.3)
|
185 (26.5)
|
22 (12.3)
|
37 (29.4)
|
|
EGFR+ status, n (%)b
|
|
Documented
|
19 (1.9)
|
1 (0.1)
|
0
|
18 (14.3)
|
|
Assumed
|
89 (8.9)
|
0
|
0
|
89 (70.6)
|
|
ALK+ status, n (%)b
|
|
Documented
|
2 (0.2)
|
0
|
0
|
2 (1.6)
|
|
Assumed
|
17 (1.7)
|
0
|
0
|
17 (13.5)
|
|
PD-L1+ status, n (%)b
|
|
Documented
|
10 (1.0)
|
3 (0.4)
|
7 (3.9)
|
0
|
|
Assumed
|
172 (17.1)
|
0
|
172 (96.1)
|
0
|
